{"podcast":{"title":"The High Court Report","slug":"the-high-court-report-7304353","podcast_index_feed_id":7304353,"rss_url":"https://feeds.captivate.fm/scotus-oral-arguments/","website_url":"https://thehighcourtreport.com","image_url":"https://artwork.captivate.fm/32e133db-cc46-422f-a13c-e80534752cea/OPERATIVE-SCOTUS-THUMBNAIL.jpg","author":"SCOTUS Oral Arguments","episode_count":500,"summary":"The High Court Report makes Supreme Court decisions accessible to everyone. We deliver comprehensive SCOTUS coverage without the legal jargon or partisan spin—just clear analysis that explains how these cases affect your life, business, and community. What you get: Case previews and breakdowns, raw oral argument audio, curated key exchanges, detailed opinion analysis, and expert commentary from a practicing attorney who's spent 12 years in courtrooms arguing the same types of cases the Supreme Court hears. Why it works: Whether you need a focused 10-minute update or a deep constitutional dive, episodes are designed for busy professionals, engaged citizens, and anyone who wants to understand how the Court shapes America. When we publish: 3-5 episodes weekly during the Court's October-June term, with summer coverage of emergency orders and retrospective analysis. Growing archive: Oral arguments back to 2020 and expanding, so you can hear how landmark cases unfolded and track the Court's evolution. Your direct line to understanding the Supreme Court—accessible, thorough, and grounded in real legal expertise.**","last_synced_at":"2026-07-02T18:20:06.779164+00:00","page_url":"https://stenobird.com/podcast/the-high-court-report-7304353"},"episode":{"title":"Safe Drug or Unsafe Criminal Act? The Mifepristone Showdown at the Supreme Court","slug":"safe-drug-or-unsafe-criminal-act-the-mifepristone-showdown-at-the-supreme-court","published_at":"2026-05-17T09:00:00+00:00","page_url":"https://stenobird.com/podcast/the-high-court-report-7304353/safe-drug-or-unsafe-criminal-act-the-mifepristone-showdown-at-the-supreme-court","show_page_url":"https://stenobird.com/podcast/the-high-court-report-7304353","url":"https://thehighcourtreport.com//safe-drug-or-unsafe-criminal-act-the-mifepristone-showdown-at-the-supreme-court","audio_url":"https://episodes.captivate.fm/episode/f7838ede-7e8b-437a-9c7b-23f7c8b897f2.mp3","summary":"Danco Laboratories, L.L.C. v. Louisiana | Nos. 25A1207, 25A1208 | Decided May 14, 2026 | Docket Link: Here Overview: The Supreme Court blocked the Fifth Circuit's nationwide order reinstating mifepristone's in-person dispensing requirement, preserving mail-order and telehealth distribution while Louisiana's APA challenge to the FDA's 2023 REMS proceeds. Question Presented: Whether the Fifth Circuit's §705 order suspending the FDA's 2023 mifepristone REMS changes should remain in effect pending appeal. Posture: District court denied preliminary relief; Fifth Circuit reversed, suspending 2023 REMS nationwide under §705. Main Arguments: Mifepristone Manufacturers (Applicants): (1) Louisiana lacks Article III standing — the 2023 REMS does not regulate Louisiana, and its sovereign and Medicaid-cost injuries depend on attenuated third-party choices the Court rejected in Alliance and Texas ; (2) The FDA's removal of the in-person requirement rested on 15 studies covering 55,000 patients and consistent adverse-event data showing no safety concerns; (3) The Fifth Circuit's order upends five years of settled distribution infrastructure, inflicting irreparable harm on manufacturers, patients, providers, and 20 states supporting the current REMS. Louisiana (Respondent): (1) Louisiana holds sovereign standing — approximately 1,000 violations of its abortion laws occur monthly, each constituting an injury to its sovereignty under Stevens , reinforced by $92,000 in Medicaid costs and $17,000 in enforcement outlays; (2) The FDA itself refuses to defend the 2023 REMS, conceding it reflected \"inadequate consideration,\" and three separate Fifth Circuit panels found the APA challenge likely meritorious; (3) Neither the public nor the FDA holds any interest in perpetuating an agency action…","meta_description":"Danco Laboratories, L.L.C. v. Louisiana | Nos. 25A1207, 25A1208 | Decided May 14, 2026 | Docket Link: Here Overview: The Supreme Court blocked the Fifth C…","key_points":[],"chapters":[],"topics":[],"duration_seconds":890,"processing_state":"not_requested","actions":[{"name":"request_transcript","method":"POST","url":"https://stenobird.com/v1/public/podcasts/the-high-court-report-7304353/episodes/safe-drug-or-unsafe-criminal-act-the-mifepristone-showdown-at-the-supreme-court/transcription-requests","description":"Idempotently request low-priority transcript generation for this episode."},{"name":"read_markdown","method":"GET","url":"https://stenobird.com/podcast/the-high-court-report-7304353/safe-drug-or-unsafe-criminal-act-the-mifepristone-showdown-at-the-supreme-court.md","description":"Read the agent-friendly Markdown representation of this episode resource."}]}}